Feedback PLC – New board appointments

Further to the publication of Feedback’s final results earlier today, the Company announces the appointment to the Board of Dr Balaji Ganeshan, Mike Hayball and Dr Alex Menys. Disclosures under Schedule 2 of the AIM Rules Dr Balaji Ganeshan, aged 33, holds or has held the following directorships and/or partnerships in the previous five years: […]

Feedback PLC – ICENI Centre & ISLCRS study to investigate whether textural features of rectal cancer on Magnetic Resonance can predict long term survival

Magnetic resonance based texture parameters as potential imaging biomarkers for predicting long term survival in locally advanced rectal cancer patients. Omer Jalil, Asim Afaq, Balaji Ganeshan, Uday Patel, Raymond Endozo, Darren Boone, Ashley Groves, David Humber, Tan Arulampalam ICENI Centre Colchester University Hospital Colchester CO4 5JL Introduction: Heterogeneity is a well-known feature of malignancy and […]

Strategic alliance between Quibim and Feedback Plc to improve prostate biopsy

From the Spanish medical website Tu hospital investiga para ti The Spin-Off of the IIS La Fe, Quibim has established a strategic alliance with UK company Feedback Plc to develop Prostate Checker, a tool that will improve the diagnosis of prostate cancer. Feedback Plc acquired last year TexRAD company dedicated to the analysis of tumor from medical […]

Feedback Plc – Presentation of Study Results

Feedback Plc – Presentation of Study Results On July 20th 2015, Feedback plc announced the successful completion of a large evaluation of TexRAD CT texture analysis (CTTA) as a pre-therapy imaging biomarker in 241 metastatic renal (kidney) cell cancer (m-RCC) patients treated with anti-angiogenic therapy (AAT – drugs that block cancer blood-vessel growth). The research […]

Feedback (FDBK) – Strategy update

Feedback plc (FDBK) is pleased to announce an update on its corporate strategy. Feedback has recently announced two joint ventures where its TexRAD texture analysis software is to be incorporated into developing new products designed specifically for the assessment and management of patients with prostate cancer and kidney stones. In the light of these exciting […]